CDKN2A and melanoma: In line with our results, recent studies have also indicated the prognostic role of CDKN2A/B in pancreatic, lung, breast, melanoma and ovarian cancers (Qiu et al., 2015[19]; Seifi et al., 2019[24]; Campa et al., 2016[4]; Schuster et al., 2014[23]).